STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRV
  4. [Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Acrivon (NASDAQ: ACRV) leaders use 1,743 shares for RSU tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Acrivon Therapeutics executives reported routine tax-related share dispositions tied to restricted stock unit vesting. A total of 1,743 common shares at $1.92 were withheld by the company to satisfy mandatory tax obligations, rather than sold in the open market.

After these withholdings, one executive directly holds 2,078,951 shares and another has 313,637 shares reported as indirectly held through spousal ownership, reflecting that both retain substantial positions following the transactions.

Positive

  • None.

Negative

  • None.
Insider Blume-Jensen Peter, Masson Kristina
Role President and CEO | EVP - Business Operations
Type Security Shares Price Value
Tax Withholding Common Stock 1,253 $1.92 $2K
Tax Withholding Common Stock 490 $1.92 $940.80
Holdings After Transaction: Common Stock — 2,078,951 shares (Direct, null); Common Stock — 313,637 shares (Indirect, See Footnote)
Footnotes (1)
  1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Tax-withheld shares 1,743 shares Common stock withheld for tax on RSU vesting
Withholding price $1.92 per share Value used for tax-withholding dispositions
Direct holdings after transaction 2,078,951 shares Common stock directly held by one executive after tax withholding
Indirect holdings after transaction 313,637 shares Common stock indirectly held through spousal ownership after withholding
Non-derivative transactions 2 dispositions Both coded F for tax-withholding on RSUs
restricted stock units financial
"upon vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
mandatory tax withholding financial
"to satisfy the mandatory tax withholding requirement"
beneficial ownership financial
"disclaims beneficial ownership of such securities except"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of her pecuniary interest therein."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026F(1)1,253D$1.922,078,951D(2)
Common Stock05/14/2026F(1)490D$1.92313,637ISee Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Blume-Jensen Peter
(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
1. Name and Address of Reporting Person*
Masson Kristina
(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirector10% Owner
XOfficer (give title below)Other (specify below)
EVP - Business Operations
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen05/18/2026
/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Acrivon Therapeutics (ACRV) insiders report in this Form 4?

Acrivon Therapeutics insiders reported that 1,743 common shares were withheld at $1.92 per share to cover tax obligations on vested restricted stock units, a standard administrative transaction rather than an open-market stock sale.

Were the Acrivon (ACRV) Form 4 transactions open-market stock sales?

No, the transactions were not open-market sales. The 1,743 Acrivon common shares were withheld by the company to satisfy mandatory tax withholding on restricted stock unit vesting, classified under code F as tax-withholding dispositions.

How many Acrivon (ACRV) shares do the executives hold after the tax withholdings?

Following the tax withholdings, one Acrivon executive directly holds 2,078,951 common shares, while 313,637 shares are reported as indirectly held through spousal ownership, indicating both individuals maintain sizable equity stakes after the transactions.

What does transaction code F mean in the Acrivon (ACRV) Form 4 filing?

Transaction code F in the Acrivon filing indicates shares were delivered to pay a tax liability or exercise price. Here, it reflects shares withheld by the issuer to meet mandatory tax withholding on restricted stock unit vesting, not discretionary stock sales.

How are spousal holdings treated in the Acrivon Therapeutics (ACRV) Form 4?

The Form 4 explains that each executive’s spouse holds some of the reported Acrivon shares. Each spouse disclaims beneficial ownership except for their pecuniary interest, meaning indirect holdings are reported with limited ownership claims per the footnotes.